Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Contineum Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Contineum Therapeutics, Inc.’s stock price such as:

• Contineum Therapeutics, Inc.’s current stock price and volume
• Why Contineum Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CTNM from analysts
• CTNM’s stock price momentum as measured by its relative strength

About Contineum Therapeutics, Inc. (CTNM)

Before we jump into Contineum Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Want to learn more about Contineum Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Contineum Therapeutics, Inc..

Contineum Therapeutics, Inc.’s Stock Price as of Market Close

As of September 14, 2026, 11:22 AM, CST, Contineum Therapeutics, Inc.’s stock price was $15.280.

Contineum Therapeutics, Inc. is up 3.1% from its previous closing price of $14.820.

During the last market session, Contineum Therapeutics, Inc.’s stock traded between $14.780 and $15.410. Currently, there are approximately 37.47 million shares outstanding for Contineum Therapeutics, Inc..

Contineum Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Contineum Therapeutics, Inc. Stock Price History

Contineum Therapeutics, Inc.’s (CTNM) price is currently down 5.91% so far this month.

During the month of September, Contineum Therapeutics, Inc.’s stock price has reached a high of $17.790 and a low of $14.610.

Over the last year, Contineum Therapeutics, Inc. has hit prices as high as $17.785 and as low as $8.600. Year to date, Contineum Therapeutics, Inc.’s stock is up 33.68%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Contineum Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 11, 2026, there was 1 analyst who downgraded Contineum Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Contineum Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Contineum Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Contineum Therapeutics, Inc. (CTNM) by visiting AAII Stock Evaluator.

Relative Price Strength of Contineum Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 11, 2026, Contineum Therapeutics, Inc. has a weighted four-quarter relative price strength of 6.59%, which translates to a Momentum Score of 76 and is considered to be Strong.

Want to learn more about how Contineum Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Contineum Therapeutics, Inc. Stock Price: Bottom Line

As of September 14, 2026, Contineum Therapeutics, Inc.’s stock price is $15.280, which is up 3.1% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Contineum Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.